Trevogrumab
Regeneron's anti-myostatin monoclonal antibody, currently being studied with semaglutide for muscle preservation.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Regeneron's targeted anti-myostatin antibody pursuing the same muscle-preservation hypothesis as bimagrumab — but with selectivity for myostatin specifically rather than the shared ActRIIB receptor.
- Class
- Anti-myostatin monoclonal antibody
- Sponsor
- Regeneron Pharmaceuticals
- Stage
- Phase 2
- Lead use case
- Muscle preservation alongside GLP-1 therapy
What it is
Trevogrumab is a fully human monoclonal antibody that binds and neutralizes mature myostatin. Unlike bimagrumab (which blocks ActRIIB and therefore neutralizes both myostatin and activin signaling), trevogrumab is selective for myostatin specifically.
Current research status
Regeneron has progressed trevogrumab through Phase 2 trials, including a program studying it in combination with semaglutide for muscle preservation during obesity treatment. Earlier Phase 2 work in sarcopenia and inclusion body myositis has informed the current obesity-pairing strategy.
Mechanistic rationale
Mature myostatin binds ActRIIB with another co-receptor (ALK4 or ALK5) to activate Smad2/3 signaling and suppress muscle protein synthesis. Trevogrumab binds the active myostatin ligand directly, preventing receptor engagement. The selectivity for myostatin (vs activin or other TGF-β family ligands) is the defining feature of the program.
Available evidence
Phase 2 obesity trial (Regeneron + semaglutide) — Reported reductions in lean-mass loss vs semaglutide alone, with the trial design specifically focused on body-composition partitioning.[1]
Earlier sarcopenia work — Phase 2 trials in older adults with sarcopenia showed modest but measurable increases in lean body mass over 24 weeks.
Why it's interesting
The myostatin-selective vs ActRIIB-blockade question is one of the more interesting unresolved scientific questions in muscle-preservation pharmacology. Bimagrumab's broader receptor blockade may produce larger effects but also broader off-target effects; trevogrumab's selectivity may produce smaller-but-cleaner effects. Whether selectivity or potency wins out clinically is a question the head-to-head data will eventually answer.
Limitations & risks
Selectivity has trade-offs. Pure anti-myostatin antibodies have historically produced smaller muscle-mass effects than broader ActRII pathway blockers in animal and human studies — myostatin is one of multiple muscle-suppressing ligands, and blocking only one may leave the others active. Whether trevogrumab's selectivity translates to meaningful muscle preservation in obesity-related rapid weight loss is the empirical question of the program.
Community discussion notes
Discussed extensively in fitness and bodybuilding communities given the long history of myostatin inhibition as a goal. The combination with semaglutide is what brought it into the mainstream metabolic-medicine conversation. Real-world use is investigational only — neither the antibody nor any equivalent grey-market product has demonstrated body-composition effects in the magnitude that fitness-community discussion sometimes implies.
The takeaway
Trevogrumab is the leading selective-anti-myostatin candidate in development for the muscle-preservation use case. Whether selectivity for myostatin specifically (vs broader ActRII-pathway blockade like bimagrumab) is the right approach is a key open question that the Phase 2/3 data will substantially clarify.
References
- Regeneron Pharmaceuticals. Trevogrumab Phase 2 obesity / muscle-preservation trial results. Corporate disclosures and peer-reviewed publications anticipated. https://pubmed.ncbi.nlm.nih.gov/?term=trevogrumab
- Latres E, et al. Anti-myostatin antibody increases muscle mass and strength in muscle wasting models. Skelet Muscle. 2015;5:34. https://pubmed.ncbi.nlm.nih.gov/26395986/